Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 86 P282 | DOI: 10.1530/endoabs.86.P282

SFEBES2022 Poster Presentations Thyroid (41 abstracts)

The future of TSH receptor antibody (TRAb) testing at university hospitals birmingham (UHB)

Imogen Milner 1 , Louis Kennedy 1 & Asad Rahim 2


1University of Birmingham Medical School, Birmingham, United Kingdom; 2University Hospitals Birmingham Trust, Birmingham, United Kingdom


Background: Graves’ disease (GD) is an autoimmune condition accounting for up to 80% of thyrotoxicosis cases.1 90% of these patients have TSH receptor antibodies (TRAbs).2 Current NICE guidance recommends testing for TRAbs in adults with confirmed thyrotoxicosis to differentiate between thyrotoxicosis with hyperthyroidism (e.g GD and toxic multinodular goitre) and thyrotoxicosis without hyperthyroidism (e.g thyroiditis).2

Objective: To evaluate the necessity of the TRAb blood test to confirm a diagnosis of Graves’ disease in patients presenting with a clinical diagnosis of thyrotoxicosis.

Methodology: We chronologically selected the first 102 patients with TRAb tests performed between January 2020 and September 2021 at UHB. Patients pregnant at the time of testing were excluded. We recorded group demographics, initial diagnosis at clinical assessment, TRAb result and post-TRAb diagnosis.

Results: Of our 102 patients, 57 (56%) had a pre-TRAb diagnosis of GD. Of this group, 49 (86%) of the patients with an initial diagnosis of GD did not have their diagnosis altered post-TRAb. For those without an initial diagnosis of GD (n=45), 28 (63%) did not have their diagnosis altered post-TRAb. In the group as a whole, 77 (75%) did not have their diagnosis altered once TRAb results were available.

Conclusions: Our audit suggests that for patients with a clinical diagnosis of GD, from an endocrinologist, TRAb testing added little benefit as it did not alter diagnosis in the majority of cases. In those without an initial diagnosis of GD, the TRAb was more useful.

Recommendations: Our audit supports the British Thyroid Association’s recommendation that TRAb testing is ‘not essential where there is a strong clinical picture of GD.3 Clinical diagnosis appears highly reliable and due to similar initial management of GD and toxic nodular goitre, not confirming a diagnosis of GD poses minimal risk to the patient.

Volume 86

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.